Storia in 3 fonti

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

Raccontata da

biopharmadive.com

milanofinanza.it

qz.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo10 g fa

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

originale

qz.com8 g fa

Novartis stock rises after MS drug remibrutinib trial results

The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies

Leggi questa versione → originale

Timeline cronologica

martedì 1 settembre 2026·biopharmadive.com
Novartis says MS pill succeeds in two large studies
Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
martedì 1 settembre 2026·milanofinanza.it
Novartis, Remibrutinib centra gli obiettivi sulla sclerosi multipla. In secondo piano lo stop a otto studi su Rap-cel | MilanoFinanza News
Ubs stima una probabilità del 50% di successo per il farmaco sperimentale Remibrutinib con vendite al picco previste a 4,5 miliardi di dollari. Nominato Federico Mambretti Country…

Novartis says MS pill succeeds in two large studies

Novartis stock rises after MS drug remibrutinib trial results

Timeline cronologica

Novartis says MS pill succeeds in two large studies

Novartis, Remibrutinib centra gli obiettivi sulla sclerosi multipla. In secondo piano lo stop a otto studi su Rap-cel | MilanoFinanza News

Novartis, Remibrutinib centra gli obiettivi sulla sclerosi multipla. In secondo piano lo stop a otto studi su…

Novartis stock rises after MS drug remibrutinib trial results